Article
TP53 mutations predict decitabine-induced complete responses in patients with myelodysplastic syndromes.
British journal of haematology - 1 Feb 2017
Chang Chun-Kang, Zhao You-Shan, Xu Feng, Guo Juan, Zhang Zheng, He Qi, Wu Dong, Wu Ling-Yun, Su Ji-Ying, Song Lu-Xi, Xiao Chao, Li Xiao
Abstract excerpt
To identify the molecular signatures that predict responses to decitabine (DAC), we examined baseline gene mutations (28 target genes) in 109 myelodysplastic syndrome (MDS) patients at diagnosis. We determined that TP53 mutations predicted complete response (CR), as 10 of 15 patients (66·7%) who possessed TP53 mutations achieved a CR. Univariate and multivariate analyses showed that TP53 mutations are the only...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.